Study guide
7.3 Phase I Biotransformation: Cytochrome P450 Monooxygenases & Non-CYP Oxidation
DABT: Diplomate of the American Board of Toxicology Exam
Track your progress as you read
Finished sections get a check mark.
1 Exam Overview & Study Design Fundamentals
1.1 Current DABT Exam Facts 1.2 Study Objectives, Hypothesis Testing & Regulatory Guideline Selection 1.3 Test System Selection, Species Models & Animal Welfare (3Rs, IACUC) 1.4 Route Selection, Dosing Regimens & Treatment Duration
2 Dose Selection, Controls & Biostatistics in Toxicology
2.1 Dose Selection Strategies: Range-Finding, Maximum Tolerated Dose (MTD) & Limit Doses 2.2 Control Groups (Negative, Vehicle, Positive, Sham) & Confounding Factors 2.3 Statistical Design, Power Analysis & Statistical Testing of Toxicological Data
3 Study Execution, GLP Compliance & Quality Assurance
3.1 Good Laboratory Practice (GLP) Regulations (FDA 21 CFR Part 58, OECD GLP) & Study Director Responsibilities 3.2 Test Article Characterization, Formulation Analysis, Stability & Homogeneity 3.3 Standard Operating Procedures (SOPs), Quality Assurance Unit (QAU) & Audit Inspections
4 Executing In Vivo, In Vitro, In Silico & Field Studies
4.1 In-Life Clinical Signs, FOB, Body Weight, Food/Water, Ophthalmology 4.2 In Vitro, In Silico (QSAR, Read-Across, PBPK, AI/ML), Field, Clinical & Epidemiologic Characterization
5 Clinical Pathology & Toxicologic Pathology
5.1 Hematology & Coagulation Parameters in Safety Evaluation 5.2 Clinical Chemistry: Biomarkers of Hepatic, Renal & Muscle Injury 5.3 Urinalysis & Specialized Biomarkers of Organ Toxicity 5.4 Toxicologic Pathology: Organ Weights, Gross Necropsy & Histopathology Interpretation
6 Specialized Toxicological Study Endpoints
6.1 Genetic Toxicology Assays: Ames Test, Chromosomal Aberrations & Micronucleus Assays 6.2 Reproductive & Developmental Toxicity Testing (ICH S5, Segments I, II, III) 6.3 Carcinogenicity Bioassays: Design, Conduct & Neoplastic Lesion Evaluation 6.4 Safety Pharmacology (Core Battery: Cardiovascular/hERG, CNS, Respiratory) & Immunotoxicology
7 Toxicokinetics & Biotransformation
7.1 Absorption & Physiological Barriers (Membrane Transport, Blood-Brain Barrier, GI Absorption) 7.2 Distribution, Plasma Protein Binding & Transporters (P-gp, OATs, OCTs, BSEP) 7.3 Phase I Biotransformation: Cytochrome P450 Monooxygenases & Non-CYP Oxidation 7.4 Phase II Biotransformation: Conjugation Pathways, Bioactivation & Detoxification
8 Cellular Mechanisms of Toxicity & Organ Pathogenesis
8.1 Oxidative Stress, Reactive Oxygen/Nitrogen Species (ROS/RNS) & Antioxidant Defenses 8.2 Cell Death Pathways: Necrosis, Apoptosis, Autophagy & Mitochondrial Dysfunction 8.3 Molecular Mechanisms of Target Organ Toxicity: Hepatotoxicity, Nephrotoxicity & Neurotoxicity
9 Hazard Identification & Evidence Integration
9.1 Hazard Identification Principles, Weight of Evidence (WoE) & Systematic Review 9.2 Carcinogen Hazard Classification Schemes (IARC, EPA Guidelines, GHS) 9.3 Agent Classes & Organ-System Toxic Responses
10 Mode of Action, AOPs & Non-Cancer Endpoints
10.1 Mode of Action (MoA) Framework & Human Relevance Evaluation 10.2 Adverse Outcome Pathways (AOP): Molecular Initiating Events, Key Events & Organ-Level Outcomes 10.3 Non-Cancer Systemic Toxicity Endpoints & Target Organ Critical Effects
11 Exposure Assessment Methodologies & Quantification
11.1 Exposure Routes, Scenarios & Pathways (Occupational, Dietary, Environmental, Consumer) 11.2 Exposure Quantification: Dose Equations, Average Daily Dose (ADD) & Lifetime Average Daily Dose (LADD) 11.3 Inhalation Dosimetry: Human Equivalent Concentrations (HEC) & Regional Gas Dose Ratios (RGDR) 11.4 Biomonitoring, Internal Dose, Fate/Transport & BCF
12 Quantitative Dose-Response Principles & Point of Departure Derivation
12.1 Dose-Response Relationships: Threshold vs Non-Threshold, Linear vs Non-Linear Models 12.2 Point of Departure (PoD) Determination: NOAEL, LOAEL & Benchmark Dose (BMD/BMDL) Modeling 12.3 Low-Dose Extrapolation, Cancer Slope Factors (CSF), Unit Risk & First-in-Human Dose
13 Health-Based Guidance Value Derivation & Uncertainty Factors
13.1 Uncertainty Factors (UFs), Interspecies/Intraspecies Extrapolation & Chemical-Specific Adjustment Factors (CSAF) 13.2 Derivation of Reference Values: RfD, RfC, ADI, TDI & Permissible Daily Exposure (PDE)
14 Risk Characterization for Non-Cancer & Cancer Health Effects
14.1 Non-Cancer Risk Characterization: Hazard Quotient (HQ), Hazard Index (HI) & Margin of Exposure (MoE) 14.2 Cancer Risk Characterization: Excess Lifetime Cancer Risk & Acceptable Risk Tolerances 14.3 Uncertainty & Sensitivity Analysis in Risk Characterization
15 Risk Management, Occupational Exposure Limits & Environmental Standards
15.1 Occupational Exposure Limit (OEL) Derivation: OSHA PELs, ACGIH TLVs & NIOSH RELs 15.2 Environmental Quality Standards: Drinking Water MCLs & Air Quality Standards (NAAQS) 15.3 Risk Management Decision-Making, Risk Communication & Socioeconomic Considerations
16 Regulatory Frameworks & Product Stewardship
16.1 Food, Drug & Cosmetic Regulation: FDA Framework, Delaney Clause & GRAS Evaluations 16.2 Chemical Substances & Environmental Regulation: EPA TSCA, FIFRA, Clean Air & Clean Water Acts 16.3 International Regulatory Harmonization: OECD, ICH Guidelines & EU REACH
17 Clinical Toxicology & Medical Management of Poisoning
17.1 Clinical Toxidromes & Initial Management of Acute Poisoning 17.2 Specific Antidotes, Mechanisms of Action & Decontamination Strategies
18 Environmental, Ecological & Public Health Toxicology
18.1 Environmental Toxicology: Fate, Transport, Bioaccumulation (log Kow, BCF) & Ecotoxicological Testing 18.2 Public Health Events, Epidemiology, Susceptible Subpopulations & Exposure Investigation
7.3 Phase I Biotransformation: Cytochrome P450 Monooxygenases & Non-CYP Oxidation
Key Takeaways Explain This Topic AI
Human hepatic CYP3A4 oxidizes a large share of drug-like xenobiotics (midazolam is a probe); CYP2D6, 2C9, 2C19, 1A2, and 2E1 cover distinct substrate maps with different induction and inhibition rules.
Induction (PXR, CAR, AhR transcriptional programs) takes days; inhibition can be immediate and can be competitive or mechanism-based; CYP2D6 is not readily induced the way CYP3A4 is.
Genetic polymorphisms (handbook II.3) in CYP2D6, CYP2C9, CYP2C19, and NAT2 change susceptibility: poor metabolizers may accumulate parent or fail to form an active metabolite (codeine → morphine via CYP2D6).
Non-CYP oxidation includes FMO (N- and S-oxidation), ADH/ALDH (ethanol), MAO (including MPTP → MPP+), epoxide hydrolase, and esterases (CES, PON1).
Dogs are poor N-acetylators (functionally deficient NAT compared with human NAT1/NAT2); do not confuse that Phase II species defect with feline UGT1A6 loss, which belongs with glucuronidation.
Last updated: September 2026
Why Phase I is a susceptibility topic
Handbook Domain II.2 wants species and pathway differences in biotransformation; II.3 adds genetic polymorphisms as a reason two humans (or two strains) do not share the same internal dose of metabolite. Phase I reactions—oxidation, reduction, hydrolysis—usually insert or expose a functional group. That group may be conjugated in Phase II, or the product may be the toxic species. Independent ExamFinch material in this section covers cytochrome P450 (CYP) families most often cited in human toxicology, how induction differs from inhibition, non-CYP oxidases, and a species acetylation difference you must not mix up with feline glucuronidation. It is not an ABT product and does not claim official approval, review, or partnership with ABT.
CYP enzymes are heme-thiolate monooxygenases in the endoplasmic reticulum. They split molecular oxygen: one atom goes to substrate (as hydroxyl, epoxide, or related product), the other to water. NADPH-CYP reductase supplies electrons. Activity in vitro is often measured in microsomes or with recombinant isoforms. S9 is the post-mitochondrial supernatant used in genotoxicity batteries because it contains microsomal CYPs plus some cytosolic enzymes.
Human CYP families you must be able to assign
CYP3A4 (with CYP3A5 in some people) oxidizes a large fraction of drug-like xenobiotics and many steroids. It is abundant in liver and small-intestinal epithelium . Midazolam 1′-hydroxylation is a classic probe. Ketoconazole , itraconazole, clarithromycin, and ritonavir inhibit CYP3A. Rifampin , carbamazepine, phenytoin, and St. John’s wort induce it via PXR (and related nuclear-receptor programs). Grapefruit furanocoumarins inactivate intestinal CYP3A and can raise oral AUC of substrates that rely on gut first-pass.
CYP2D6 oxidizes many psychotropics, beta-blockers, and codeine (O-demethylation to morphine ). It is highly polymorphic (poor, intermediate, extensive, ultrarapid metabolizers) and is not readily inducible by the PXR/CAR ligands that raise CYP3A4. Inhibitors include quinidine, fluoxetine, and paroxetine. An ultrarapid metabolizer can form excess morphine from codeine; a poor metabolizer gets little analgesia and more parent.
CYP2C9 oxidizes S-warfarin , phenytoin, and several NSAIDs. CYP2C9*2 and *3 reduce function and increase bleeding risk on standard warfarin doses. Inhibitors include fluconazole and amiodarone.
CYP2C19 activates clopidogrel and oxidizes some proton-pump inhibitors and antidepressants. Loss-of-function alleles (*2, *3) are common in some East Asian populations; *17 increases function. Poor metabolizers activate less clopidogrel.
CYP1A2 oxidizes caffeine , theophylline, and some aromatic amines. Smoking and charbroiled food (PAHs) induce CYP1A enzymes through the aryl hydrocarbon receptor (AhR) , the same receptor classically cited for TCDD-like induction of CYP1A1/1B1 extrahepatically. Fluvoxamine inhibits CYP1A2.
CYP2E1 oxidizes low-molecular-weight solvents and alcohols : ethanol, benzene, acetaminophen (a fraction to NAPQI ), carbon tetrachloride , chloroform, and vinyl chloride. It is induced by chronic ethanol , fasting /acetone, and isoniazid, and it sits preferentially in centrilobular hepatocytes—the zone that dies first in CCl4 and APAP overdose. Competitive inhibition by ethanol can spare APAP bioactivation during drinking and then unmask a large induced CYP2E1 pool after ethanol is gone; that timing question is a classic interpretation trap.
Induction versus inhibition
Inhibition can begin with the first dose: reversible competition at the active site, or mechanism-based (suicide) inactivation that destroys enzyme until new protein is made (some macrolides, grapefruit furanocoumarins, a subset of HIV protease inhibitors). Induction requires transcription and new enzyme (PXR → CYP3A4/2B6/2C; CAR → CYP2B6 and some 2C/3A; AhR → CYP1A). Clinical onset is days , not minutes. Autoinduction (carbamazepine) lowers parent over the first weeks. Do not call a same-day AUC drop “induction.” Do not call CYP2D6 “induced by rifampin” as if it were CYP3A4.
Polymorphisms as susceptibility (II.3)
A poor metabolizer of a detoxifying CYP accumulates parent (phenytoin and CYP2C9). A poor metabolizer of a bioactivating CYP is relatively protected (less NAPQI if CYP2E1 activity is low; less morphine from codeine if CYP2D6 is absent). An ultrarapid CYP2D6 genotype does the reverse for codeine. NAT2 slow acetylation is a Phase II polymorphism, but exam items mix it with CYP stories: slow acetylators accumulate isoniazid and have more peripheral neuropathy if pyridoxine is inadequate, and they handle some aromatic amines differently. Record the enzyme, the direction (gain or loss), and whether the metabolite is toxic or therapeutic.
Non-CYP oxidation and hydrolysis
Flavin-containing monooxygenases (FMOs) use FAD and NADPH to N- and S-oxidize many soft nucleophiles (including trimethylamine via FMO3 ; FMO3 deficiency is trimethylaminuria). FMOs are not heme CYPs, are relatively heat-labile in vitro, and are not induced by the same PXR/AhR programs.
Alcohol dehydrogenase (ADH) in cytosol oxidizes ethanol to acetaldehyde (NAD+). Aldehyde dehydrogenase (ALDH) , largely mitochondrial ALDH2 , oxidizes acetaldehyde to acetate. Disulfiram inhibits ALDH. ALDH2*2 (common in some East Asian populations) raises acetaldehyde and flushing—another II.3 susceptibility example.
Monoamine oxidases (MAO-A, MAO-B) on the outer mitochondrial membrane oxidatively deaminate amines. MAO-B converts the protoxin MPTP to MPP+ , which kills nigrostriatal neurons; MAO-B inhibitors can block that bioactivation in experimental systems.
Microsomal epoxide hydrolase (mEH, EPHX1) adds water to epoxides, yielding trans-dihydrodiols. That is detoxification for many arene oxides, but for benzo[a]pyrene the diol is a stepping-stone to the diol-epoxide (taught with Phase II in 7.4). Esterases include carboxylesterases (CES) that hydrolyze many esters and carbamates, plasma butyrylcholinesterase, acetylcholinesterase (nerve-agent target), and paraoxonase (PON1) that hydrolyzes paraoxon . PON1 status is another susceptibility modifier for some organophosphates.
Species difference: dogs as poor acetylators
N-acetylation is a Phase II reaction (acetyl-CoA, cytosolic NAT). It is taught here because species ranking is a standard II.2 trap next to CYP tables. Dogs (and foxes) have functionally deficient NAT activity and are poor N-acetylators of many aromatic amines and hydrazines. Humans express NAT1 (wide tissue distribution) and hepatic/intestinal NAT2 , and NAT2 is polymorphic (slow versus rapid acetylators). Do not say dogs are rapid NAT2 metabolizers. Do not use the dog acetylation defect as a stand-in for cat phenolic glucuronidation deficiency (UGT1A6)—that conjugation gap is a 7.4 topic. A dog TK package can therefore miss an acetylated metabolite that humans form, or accumulate an aromatic amine that humans would acetylate.
CYP3A first-pass: ketoconazole and midazolam, rewritten
Oral midazolam undergoes substantial first-pass extraction by CYP3A in enterocytes and hepatocytes ; oral bioavailability is often on the order of ~30% because both gut and liver extract parent. Ketoconazole is a strong CYP3A inhibitor . When oral ketoconazole is given for a few days and then oral midazolam is repeated, midazolam AUC and Cmax rise several-fold to more than ten-fold in published interaction studies, because both intestinal and hepatic extraction fall . If midazolam is given intravenously , the intestinal first-pass is already bypassed, so the fold-increase is typically smaller than after oral dosing, though hepatic CYP3A inhibition still slows systemic clearance. This is an extraction-and-route lesson, not a claim that ketoconazole “binds midazolam in the gut as an insoluble salt.” Sort route , which CYP , and inhibition versus induction before you interpret an AUC change.
Enzyme Prototype substrates / probes Induction, inhibition, polymorphism notes
CYP3A4/5 Midazolam, many drugs, some steroids PXR inducers (rifampin); azole/macrolide/ritonavir inhibition; gut+liver first-pass
CYP2D6 Codeine → morphine; many CNS drugs Highly polymorphic; not readily PXR-induced; quinidine-class inhibitors
- CYP2C9 S-warfarin, phenytoin, some NSAIDs *2/*3 reduced function; fluconazole inhibition
- CYP2C19 Clopidogrel activation; some PPIs *2/*3 poor metabolizers; *17 gain of function
- CYP1A2 Caffeine, theophylline, some aromatic amines AhR/PAH/smoking induction; fluvoxamine inhibition
CYP2E1 Ethanol, APAP → NAPQI, CCl4, benzene Ethanol/fasting induction; centrilobular; competitive ethanol interaction
- FMO N- and S-oxidation; FMO3/trimethylamine Not a heme CYP; poorly inducible by PXR/AhR
- ADH/ALDH Ethanol → acetaldehyde → acetate Disulfiram and ALDH2*2 raise acetaldehyde
- MAO Amines; MPTP → MPP+ (MAO-B) Mitochondrial outer membrane
- Realistic scenario
A first-in-human protocol uses oral midazolam as a CYP3A probe on day −1, starts a strong azole antifungal on day 1, and repeats oral midazolam on day 5. AUC rises about an order of magnitude. The team then claims “the azole induced a new CYP” because a metabolite peak appeared earlier. That is backwards: ketoconazole-class azoles inhibit CYP3A ; an earlier metabolite peak would need a different explanation (assay interference, another isoform). Switching the second midazolam dose to IV should shrink the fold-change if gut CYP3A first-pass was a large part of the oral interaction. A parallel dog study that fails to form an acetylated aromatic-amine metabolite that humans make is a poor-acetylator species finding, not proof that canine CYP2D6 is missing.
Traps
Treating CYP2D6 as rifampin-inducible like CYP3A4.
Calling same-day AUC collapse “induction.”
Equating dog NAT deficiency with cat UGT1A6 deficiency.
Forgetting intestinal CYP3A when only hepatic microsomes were measured.
Assuming every solvent is a CYP3A4 substrate; small halogenated aliphatics often run through CYP2E1.